• Molecular NameAripiprazole
  • Synonymaripiprazole; OPC 31; OPC-14597
  • Weight448.394
  • Drugbank_IDDB01238
  • ACS_NO129722-12-9
  • Show 2D model
  • LogP (experiment)4.537
  • LogP (predicted, AB/LogP v2.0)5.23
  • pka7.6
  • LogD (pH=7, predicted)4.53
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-4.48
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds7
  • TPSA44.81
  • StatusFDA approved
  • Administrationoral (via tablets, orodispersable tablets, and oral solution); intramuscular
  • PharmacologyAn atypical antipsychotic and antidepressant used in the treatment of schizophrenia, bipolar disorder, and clinical depression.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability87.0
  • Protein binding99.0
  • Volume of distribution (VD)4.9 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmliver
  • Half life47 h
  • Excretionfeces and urine
  • Urinary Excretion<1
  • Clerance0.83 ml/min/kg
  • ToxicityCommonly observed adverse events associated with the use of aripiprazole in patients with bipolar mania (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) are constipation, akathisia, sedation, tremor, restlessness, extrapyramidal disorders.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A